Home >Research Technology Management>Technology for Licensing
Anti-infective compounds (Tuberculosis IPA)
- US Patent Issued: 8865734
- New Zealand Patent Issued: 602311
Priscille Brodin, Sunhee Kang
Stage of Development
The invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
Tuberculosis (TB) is one of the most widespread disease in the world, killing approximately 1 million every year. Current therapeutic drugs for TB takes long to cure and can be toxic. There is no cure for resistant TB. The new therapeutic drugs for multi-resistant TB will save millions of lives and bring revenue of 400 billion won every year. These compounds are the novel drug candidates to treat TB.
The applications for this invention went national phase of international application PCT/EP2011/001345 which claims the benefit of US provisional applications 61/315,113 and 61/440,937. The patent applications were filed in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico, New Zealand, Philippine, Russia, USA, Vietnam, South Africa, Brazil, India, Indonesia, Singapore, Thailand, and in Hong Kong. The US and New Zealand application were issued on October 21 2014, and on December 2 2014.